Revalesio

Revalesio is a private, clinical-stage biotech founded in 2005 and based in Tacoma, Washington. The company is developing a novel class of drugs using a proprietary fluid physics technology to create charge-stabilized nanostructures (CSN), with its lead program RNS60 in Phase 2 development for ischemic stroke recovery. With a leadership team boasting deep pharmaceutical industry and neurology expertise, Revalesio is targeting significant unmet needs in stroke rehabilitation and age-related neurological disorders, though it faces the inherent risks of clinical development and future capital needs.

Proprietary fluid physics platform that creates Charge-Stabilized Nanostructures (CSNs) in saline solution. This electrokinetically altered solution (RNS60) is designed to activate cellular signaling pathways (e.g., PI3K/Akt) to stimulate mitochondrial biogenesis, enhance ATP production, and reduce inflammation.

The stroke recovery space has limited pharmacologic options, but is highly competitive with many investigational approaches. In neurodegenerative diseases, competition is intense from large pharma and biotech firms exploring amyloid, tau, inflammation, and other mechanisms, though few directly target mitochondrial biogenesis.